Myovant Sciences Ltd
NYSE:MYOV
Myovant Sciences Ltd
NYSE:MYOV
Price:
26.98 USD
-0.04%
Market Closed
Updated:
May 2, 2024
Myovant Sciences Ltd
Operating Income
|
Myovant Sciences Ltd
Operating Income Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Myovant Sciences Ltd
NYSE:MYOV
|
Operating Income
-$146.9m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Operating Income
-$171.3m
|
CAGR 3-Years
-154%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Operating Income
-$175.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Income
-$189.4m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Income
-£59.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Income
£53m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
See Also
What is Myovant Sciences Ltd's Operating Income?
Operating Income
-146.9m
USD
-146.9m
USD
Based on the financial report for Dec 31, 2022, Myovant Sciences Ltd's Operating Income amounts to -146.9m USD.
What is Myovant Sciences Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-5%
-5%
Over the last year, the Operating Income growth was 31%. The average annual Operating Income growth rates for Myovant Sciences Ltd have been 20% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
